Policy & Regulation
Humanigen's Budget Impact Model Demonstrates Lenzilumab's Potential Positive Economic Value in Hospitalized COVID-19 Patients
12 October 2021 - - A manuscript describing US-based biopharmaceutical company Humanigen, Inc's (NASDAQ: HGEN) budget impact model for the treatment of patients hospitalized with COVID-19 is available on medRxiv, the company said.

These results highlight the value of selecting the right treatment for the right hospitalized patients during this time of unprecedented pressure on health systems.

The cost to care for a COVID-19 patient in the ICU can significantly exceed USD 100,000 and average costs for patients on invasive mechanical ventilation in ICU amount to USD 78,245 per patient. Lenzilumab is an investigational product and is not currently authorized or approved in any country.

Humanigen, Inc. (NASDAQ: HGEN), is a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called 'cytokine storm'. Lenzilumab is a first-in class antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF).

Results from preclinical models indicate GM-CSF is an upstream regulator of many inflammatory cytokines and chemokines involved in the cytokine storm.

Early in the COVID-19 pandemic, investigation showed high levels of GM-CSF secreting T cells were associated with disease severity and intensive care unit admission.

Humanigen's Phase 3 LIVE-AIR study suggests early intervention with lenzilumab may prevent consequences of a full-blown cytokine storm in hospitalized patients with COVID-19.

Humanigen is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 and CD19-targeted CAR-T cell therapies and is also exploring the effectiveness of lenzilumab in other inflammatory conditions such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation, eosinophilic asthma, and rheumatoid arthritis.